Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Dredge

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cancer Immunology, Immunotherapy : CII|November 15, 2008
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsChristine Galustian, Brendan Meyer, Marie-Christine Labarthe, et al.
Journal of Medicinal Chemistry|March 31, 2012
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasisVito Ferro, Ligong Liu, Ken D Johnstone, et al.
Oncogene|August 7, 2023
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interactionUpasana Ray, Prabhu Thirusangu, Ling Jin, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 6, 2021
A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitisGeraldine Buitrago, Darren Pickering, Roland Ruscher, et al.
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesBoris Winterhoff, Luisa Freyer, Edward Hammond, et al.
Oncotarget|September 18, 2015
HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancerSusmita Mondal, Debarshi Roy, Juliana Camacho-Pereira, et al.
Journal of Medicinal Chemistry|February 5, 2010
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growthKen D Johnstone, Tomislav Karoli, Ligong Liu, et al.
Drug Delivery and Translational Research|January 4, 2026
Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenograftsCara Moloney, Phoebe McCrorie, Amr ElSherbeny, et al.
ACS Central Science|June 1, 2022
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 InteractionScott E Guimond, Courtney J Mycroft-West, Neha S Gandhi, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer Immunology, Immunotherapy : CII|November 15, 2008
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsChristine Galustian, Brendan Meyer, Marie-Christine Labarthe, et al.
Journal of Medicinal Chemistry|March 31, 2012
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasisVito Ferro, Ligong Liu, Ken D Johnstone, et al.
Oncogene|August 7, 2023
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interactionUpasana Ray, Prabhu Thirusangu, Ling Jin, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 6, 2021
A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitisGeraldine Buitrago, Darren Pickering, Roland Ruscher, et al.
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesBoris Winterhoff, Luisa Freyer, Edward Hammond, et al.
Oncotarget|September 18, 2015
HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancerSusmita Mondal, Debarshi Roy, Juliana Camacho-Pereira, et al.
Journal of Medicinal Chemistry|February 5, 2010
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growthKen D Johnstone, Tomislav Karoli, Ligong Liu, et al.
Drug Delivery and Translational Research|January 4, 2026
Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenograftsCara Moloney, Phoebe McCrorie, Amr ElSherbeny, et al.
ACS Central Science|June 1, 2022
Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 InteractionScott E Guimond, Courtney J Mycroft-West, Neha S Gandhi, et al.
Pageof 4